3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials.
Shares of these drugmakers could jump if the data from the studies is positive.
All three companies have attractive prospects beyond that.
10 stocks we like better than Eli Lilly ›
Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts. Putting aside the fact that it's impossible to predict the outcome of a clinical trial beforehand, even when the results are up to Wall Street's standards, it's hardly worth investing in the company unless there are other good reasons to think it will perform well over long periods.
That's why you may want to take a closer look at Eli Lilly (NYSE: LLY), Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX). All three drugmakers should release results from key clinical trials within the next 18 months, and all three have strong prospects for the next five years at least.
1. Eli Lilly
In April, Eli Lilly reported positive phase 3 results for its oral GLP-1 candidate, orforglipron. While the market reacted positively to this development, the study in question focused on diabetes patients and used A1c reduction as its primary endpoint. All eyes will be on the company's ongoing late-stage studies for orforglipron in obesity; it should release data from at least one of those clinical trials within the next year.
Eli Lilly's work in weight management has taken center stage in the past few years. The pharmaceutical leader could, once again, make a breakthrough by being one of the first to launch a highly effective oral GLP-1 anti-obesity drug. Since current options are administered subcutaneously, you can expect orforglipron to reach a reasonable level of success on the market -- but that's only if it performs well in phase 3 obesity studies. If it fails to do so, Lilly's shares could plunge.
Even so, the stock should still be a buy. True, orforglipron would strengthen Lilly's already robust lineup. But even if it falls short of expectations in late-stage studies, the company has several other candidates in development, including retatrutide, which is also in phase 3 trials.
Meanwhile, Lilly continues to generate consistent financial results. Revenue and earnings have been growing at a good clip, and that should continue for the foreseeable future.
Lastly, Eli Lilly is an excellent dividend growth stock. Although results from phase 3 trials for orforglipron in obesity will be important to monitor, the stock should perform well over the long run, regardless of the outcome of these trials.
2. Summit Therapeutics
Summit Therapeutics is developing ivonescimab, a cancer medicine it licensed from Akeso, a China-based biopharma. Ivonescimab is already approved in China; however, Summit needs to conduct clinical trials elsewhere to support approval in the U.S., Europe, and other regions where it holds marketing rights.
At least one of these studies will be of particular interest to investors. Summit is testing its crown jewel in a late-stage trial against Merck 's Keytruda in patients with non-small cell lung cancer (NSCLC), in a study called Harmoni-3. Enrollment in the study is ongoing, and there is a good chance we'll see top-line data from it by the end of next year.
Summit's stock soared when it reported that ivonescimab did better than Keytruda at reducing the risk of recurrence or death in NSCLC patients, in a study conducted in China. However, reproducing this result elsewhere could, once again, jolt the stock price. On the flip side, Summit's share price will move in the wrong direction if the results aren't what Wall Street expects.
Should you buy the stock? To me, Summit Therapeutics' prospects for the next five years seem attractive. Ivonescimab is being tested across a range of different cancers, and it looks highly promising in NSCLC, which could be its most important market.
Even with the possibility that it may not perform as well in studies outside of China, having already been approved by regulatory authorities in one region reduces the risk of significant clinical and regulatory setbacks. Ivonescimab looks like a potential pipeline in a drug. And if you invest in Summit Therapeutics now, you might reap the benefits of its leading candidate's potential.
3. Vertex Pharmaceuticals
Vertex Pharmaceuticals is a proven innovator. The company's strategy is to develop breakthrough medicines where there's a high unmet need. One of Vertex's new targets is type 1 diabetes (T1D). There are no cures for this chronic disease, but the biotech's candidate zimislecel could be a functional cure, in the sense that it could recover patients' ability to produce their own insulin -- something that people with T1D can't do.
In the phase 1/2 portion of an ongoing phase 1/2/3 clinical trial, 10 of 12 patients who received zimislecel were insulin-free after a one-year follow-up. All 12 were free of severe hypoglycemic events after 90 days.
Vertex should have data from the late-stage portion of this ongoing clinical trial within the next year. Positive results will be well received. The company also aims to submit regulatory applications for this product sometime in 2026. Zimislecel should be a nice addition to Vertex's portfolio.
The biotech remains the leader in the market for drugs that treat the underlying genetic causes of cystic fibrosis, a business that is still helping it drive strong revenue and earnings growth. Furthermore, Vertex has added several medicines to its portfolio over the past five years, including Journavx for acute pain and Casgevy for two rare blood-related disorders.
Vertex Pharmaceuticals' pipeline also has promising programs beyond zimislecel. Well beyond the announcement of clinical-trial results for this promising T1D therapy, the stock will be in an excellent position to perform.
Should you invest $1,000 in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!*
Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 21, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
28 minutes ago
- Globe and Mail
Can Buying $10,000 of Nvidia Stock Still Make You a Millionaire?
Key Points Nvidia would have to grow to nearly 4x last year's global GDP to turn $10,000 into $1 million. Achieving this goal is theoretically possible, but highly improbable. 10 stocks we like better than Nvidia › If you had invested $10,000 in Nvidia (NASDAQ: NVDA) on the day of its initial public offering in 1999 and never sold, you'd have a whopping $42.4 million today. Even if you had waited until 2015 to buy $10,000 of the stock and held on for the wild ride, your investment would be worth roughly $3.58 million now. But, as the old saying goes, hindsight is 20/20. Can buying $10,000 of Nvidia stock still make you a millionaire? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » What it would take Let's first address what it would take for a $10,000 investment in Nvidia to make you a millionaire. The math is simple: Since $1 million divided by $10,000 is 100, Nvidia would need to deliver a 100x gain. Most stocks aren't able to produce that kind of return, even over a lifetime. However, Nvidia has done it in less than nine years. Admittedly, it's hard to envision Nvidia doing it again. After all, the GPU maker now sports a market cap of over $4.2 trillion -- the highest valuation for any company ever. To turn $10,000 into $1 million, Nvidia's market cap would have to grow to a mind-blowing $420 trillion. To put that figure into perspective, the U.S. GDP last year was roughly $29.2 trillion. The GDP for the entire world was around $110.5 trillion. All Nvidia would have to do to make you a millionaire with a $10,000 investment is to grow to 3.8 times the economic output of every country on the planet. Easy, peasy, right? Potential scenarios It's hard to envision how Nvidia could grow 100x. However, I can come up with two potential scenarios where it could at least theoretically happen. The first scenario involves Nvidia achieving a revolutionary breakthrough that gives it a monopoly on technology that everyone wants. Maybe the company builds a teleportation device that allows people and products to be instantly transported anywhere. Perhaps a more likely goal would be to create AI superintelligence, an artificial general intelligence (AGI) system that's smarter than any human who has ever lived. Nvidia has teamed up with partners, including Turing, who are trying to develop AGI systems. The company's GEAR group (GEAR stands for "generalist embodied agent research") is trying to build foundation models, agents, and robots that might eventually achieve AGI. The second scenario requires time and consistently strong earnings growth. Nvidia's earnings jumped 31% year over year in the first quarter of 2025. Stock prices tend to track earnings growth over the long term. If we assume that Nvidia continues to grow by 31% for the next 17 or so years, its share price would increase by 100x. However, to deliver such stellar growth over such a long period, Nvidia might need a game-changing breakthrough mentioned in the first scenario. Facing long odds Is it possible that buying $10,000 of Nvidia stock right now could make you a millionaire? Sure. Is it probable? No way. The odds against Nvidia delivering a 100x gain are enormous. Of course, that's true for pretty much any other stock. However, I suspect that Nvidia could still make investors millionaires. It'll just take more money and potentially a long time. If you want $10,000 to turn into $1 million, though, you might have to find a smaller stock with tremendous growth prospects -- in other words, another Nvidia of 10 to 20 years ago. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
Globe and Mail
37 minutes ago
- Globe and Mail
The Stock Warren Buffett Spent $78 Billion Buying Over the Last 7 Years Is Slumping, and It Begs the Question: Has the Oracle of Omaha Lost His Touch?
Key Points Warren Buffett has purchased close to $78 billion worth of his favorite stock since the midpoint of 2018 -- and you won't find it listed in Berkshire Hathaway's quarterly 13F filings. However, Berkshire's billionaire chief hasn't spent a dime buying shares of this stock for at least three quarters -- and there's a good reason why. Buffett sticking to his roots and purposefully sitting on his hands until valuations make sense shouldn't be misconstrued as weakness. 10 stocks we like better than Berkshire Hathaway › Berkshire Hathaway 's (NYSE: BRK.A)(NYSE: BRK.B) billionaire CEO Warren Buffett is widely viewed as Wall Street's greatest money manager. Without relying on fancy charting software or algorithms, the aptly named Oracle of Omaha became one of the richest people in the world and watched Berkshire grow into one of only 11 public companies worldwide to ever hit a $1 trillion valuation. Buffett's track record -- he's overseen a 5,868,186% cumulative return in Berkshire Hathaway's Class A shares (BRK.A) in six decades -- has earned him a huge following, which includes investors who aim to mirror his trading activity. But with Warren Buffett's most-purchased stock over the last seven years recently falling more than 10% as the broad-based S&P 500 and growth-fueled Nasdaq Composite power to fresh all-time highs, the question has to be asked: Has Berkshire's billionaire CEO lost his touch? Warren Buffett's favorite stock is a company near and dear to his heart Most investors track the Oracle of Omaha's buying and selling activity by following Berkshire Hathaway's quarterly Form 13F filings. This required filing for institutional investors with at least $100 million in assets under management concisely lists all buying and selling activity from the previous quarter. However, there's a catch: Buffett's favorite stock to buy isn't listed in his company's quarterly filed 13Fs. To get the skinny on this top stock, you'll need to dig into Berkshire Hathaway's quarterly operating results. On the final page of each quarterly report, just prior to the executive certifications, you'll find a detailed breakdown of exactly how much Wall Street's most-revered billionaire money manager spent on his favorite stock (cue the dramatic music)... which happens to be shares of his own company. Prior to July 2018, Warren Buffett and now-late right-hand man Charlie Munger were only allowed to repurchase shares of Berkshire Hathaway stock if it fell to or below 120% of book value (i.e., no more than 20% above listed book value). Unfortunately, Berkshire's stock never fell to or below this line-in-the-sand threshold, which resulted in no buyback activity. On July 17, 2018, Berkshire's board amended and simplified the rules governing buybacks to two criteria. It allowed the Oracle of Omaha to repurchase shares with no ceiling or end date as long as: Berkshire has at least $30 billion in combined cash, cash equivalents, and U.S. Treasuries on its balance sheet; and Buffett views shares of his company as intrinsically cheap. This latter point is purposefully vague so as to give Buffett the discretion to put his company's capital to work via buybacks whenever he feels it's appropriate. Between July 1, 2018, and March 31, 2025, Berkshire's billionaire chief bought back almost $78 billion worth of his company's shares. This is more than Buffett has spent buying Berkshire's existing stakes in Apple, Bank of America, American Express, Coca-Cola, and Chevron, combined. But the Oracle of Omaha's favorite stock is slumping. As of this writing on July 23, it's down more than 10% from its all-time closing high in early May. Perhaps more importantly, it's underperforming the benchmark S&P 500 on a year-to-date basis. Berkshire Hathaway's slump is a sign of Buffett's resolve and shouldn't be confused with weakness With Berkshire's billionaire chief set to turn 95 in less than five weeks, as well as retiring from the CEO role at the end of this year, few investors would fault him for losing his touch. But what we're witnessing with Berkshire's stock at the moment isn't a sign of Buffett failing. Rather, it's validation of his resolve and investment philosophies. During his six decades as CEO, Buffett has bent a few of his own unwritten investment rules. For instance, while he's often viewed as a long-term investor, he and his top advisors purchased shares of gaming giant Activision Blizzard in 2022 as a short-term arbitrage opportunity given Microsoft 's $95-per-share all-cash offer to acquire the company. But the one investment philosophy Warren Buffett hasn't wavered on in six decades is his desire to get a good deal. Value is of the utmost importance to Berkshire Hathaway's billionaire chief. No matter how much he appreciates a company's competitive edge, brand, and/or management team, he's not going to buy shares if the valuation doesn't make sense. When Buffett green-lit the cumulative purchase of nearly $78 billion worth of his favorite stock over 24 quarters (six years), Berkshire Hathaway stock consistently traded at a 30% to 50% premium to its book value. But between July 1, 2024, and March 31, 2025, Buffett hasn't spent a dime to repurchase his company's stock. The reason? Berkshire's premium to book climbed to between 60% and 80%. Even shares of the Oracle of Omaha's own company are off-limits when the valuation no longer makes sense. BRK.A Price to Book Value data by YCharts. However, Buffett's cold-turkey approach with his own company's stock isn't unique. He's been a net-seller of equities for 10 consecutive quarters, with $174.4 billion more in stocks sold than purchased. Back in 2001, in an interview with Fortune magazine, Buffett referred to the market-cap-to-GDP ratio as, "probably the best single measure of where valuations stand at any given moment." This valuation tool, which divides the cumulative value of all public companies by U.S. gross domestic product (GDP), has averaged a multiple of 85% when back-tested to 1970. This is to say that the aggregate value of all publicly traded stocks has equaled about 85% of U.S. GDP over 55 years. As of the closing bell on July 22, the " Buffett Indicator," as this valuation measure is now more-commonly known, hit a record high of 212.23%! Value isn't just hard to come by in this market -- it's practically nonexistent. What we're witnessing from Buffett isn't weakness. Rather, we're seeing a time-tested investor sticking to his roots and purposefully sitting on his hands until valuations make sense. Though there's no timeline as to when valuations will fall back into Warren Buffett's (or successor Greg Abel's) wheelhouse, patience has proved to be a virtue and substantial moneymaker in the past for Berkshire's CEO and the company's shareholders. Should you invest $1,000 in Berkshire Hathaway right now? Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
National Post
3 hours ago
- National Post
The Open Group Launches The Open Group Open Digital Transformation™ Forum
Article content Article content SAN FRANCISCO — The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. Article content By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. Article content 'The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation,' commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. 'By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices.' Article content Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. Article content The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. Article content 'Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge,' said Steve Nunn, President and CEO of The Open Group. 'Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment.' Article content The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Article content Article content Article content Article content Contacts Article content Media contact Article content Article content Article content Article content
